We have recently shown that the prostaglandin E 2 (PGE 2 ) receptor EP 3 plays an important role in suppression of colon cancer cell proliferation and that its deficiency enhances late stage colon carcinogenesis. Here we examined the effects of EP 3 -deficiency on two-stage skin carcinogenesis. 7,12-Dimethylbenz[a]anthracene (50 mg/ 200 ml of acetone) was thus applied to the back skin of female EP 3 -knockout and wild-type mice at 8 weeks of age, followed by treatment with 12-O-tetradecanoylphorbol-13-acetate (5 mg/200 ml of acetone) twice a week for 25 weeks. First tumor appearance was observed in EP 3 -knockout mice at week 10, which was 3 weeks later than in EP 3 wild-type mice, and multiplicity observed at week 11 was significantly lower in the EP 3 -knockout case. However, histological examination showed that the tumor incidence and multiplicity at week 25 were not significantly changed in knockout mice and wild-type mice (incidence, 19/19 versus 23/24; multiplicity, 3.58 AE 0.51 versus 3.17 AE 0.63, respectively). Interestingly, there were no squamous cell carcinomas (SCCs) in the EP 3 -knockout mice, while SCCs were observed in 3 out of 24 wild-type mice. Furthermore, benign keratoacanthomas only developed in EP 3 -knockout mice (6/19 versus 0/24, P 5 0.01). The results suggest that PGE 2 receptor EP 3 signaling might contribute to development of SCCs in the skin.
Introduction
Prostaglandins are lipid autacoids synthesized by cyclooxygenase (COX) in response to numerous growth factors and environmental stimuli. Two isoforms of COXs have been described, the constitutively and ubiquitously expressed COX-1 and the inducible COX-2. Overproduction of prostaglandins attributable to overexpression of COX-2 in various tumors is critical for epithelial carcinogenesis and provides a target for cancer chemoprevention by non-steroidal antiinflammatory drugs (NSAIDs) (1) (2) (3) (4) (5) . Furthermore, there is a large amount of evidence from epidemiological and pharmacological studies that COX inhibitors exhibit chemopreventive activities for various malignancies in humans, including skin cancer (6, 7) . Recent studies of chemical carcinogenesis in COX-2-overexpressing transgenic mice demonstrated a promotive role of COX-2 in tumorigenesis in the skin and breast epithelium (8, 9) . A tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), was found to increase the epidermal prostaglandin E 2 (PGE 2 ) in mouse skin, and thus appears to be critical for TPA-induced hyperproliferation (10) . PGE 2 exerts its biological action through binding to four specific receptor subtypes, EP 1 , EP 2 , EP 3 and EP 4 , with seven transmembrane domains. Activation of the EP 1 receptor is associated with increases in intracellular Ca 2þ and the EP 2 and EP 4 receptors are known to be coupled to Gs protein and stimulate cAMP production by activation of adenylate cyclase. In contrast, the major signaling pathway for the EP 3 receptor is inhibition of adenylate cyclase via Gi. Several isoforms are also generated by alternative splicing from the single EP 3 receptor gene, and these exhibit other functions through activation via G proteins other than Gi (11) .
Previously, we examined the role of PGE 2 receptor subtypes in intestinal carcinogenesis using knockout mice, and the results showed that formation of aberrant crypt foci (ACF), putative preneoplastic lesions, induced by azoxymethane (AOM) was decreased in the EP 1 and EP 4 knockout cases, suggesting involvement of the receptors in ACF formation (12, 13) . Moreover, homozygous deletion of the gene encoding the EP 2 receptor results in decrease of intestinal polyp formation in Apc gene-deficient mice (14) . Recently, we also examined roles of the EP 3 receptor in AOM-induced long-term colon carcinogenesis using EP 3 receptor-knockout mice, and obtained evidence that it suppresses cell proliferation, downregulation enhancing late stage colon carcinogenesis (15) .
In the present study, we examined two-step skin carcinogenesis with dimethylbenz[a]anthracene (DMBA) and TPA (16) in EP 3 -knockout mice. These mice exhibited benign tumor formation, while wild-type mice developed malignant squamous cell carcinomas (SCCs). The results indicate that the EP 3 receptor may play a critical role in the development of malignancies in skin carcinogenesis.
Materials and methods

Animals
Mice lacking EP 3 receptor gene were generated as reported previously (17) and were backcrossed to the C57BL/6Cr strain for 10 generations. Female EP 3 receptor-deficient mice were used at 6 weeks of age. Genotypes of the knockout mice were confirmed by PCR according to the method described previAbbreviations: ACF, aberrant crypt foci; AOM, azoxymethane; COX, cyclooxygenase; DMBA, 7,12-dimethylbenz[a]anthracene; PGE 2 , prostaglandin E 2 ; SCC, squamous cell carcinoma; TPA, 12-O-tetradecanoylphorbol-13-acetate.
ously (12) . The animals were housed in plastic cages at 24 AE 2 C and 55% relative humidity with a 12/12 h light/dark cycle. Water and basal diet (AIN-76A; CLEA Japan, Tokyo) were given ad libitum. Body weights and food intake were measured weekly.
Two-stage skin carcinogenesis experiments
Initiation was achieved by a single application of 50 mg of DMBA dissolved in 200 ml of acetone to the skin of the backs of female EP 3 receptor-deficient homozygous (EP 3
À/À
) and wild-type mice at 8 weeks of age. From week 1, after the initiation, a 5 mg aliquot of TPA dissolved in 200 ml of acetone was applied to the initiated skin parts of the mice, twice a week for 25 weeks, as described previously (18) . Skin tumors were noted grossly for their location, number and diameters, measured with calipers, and digital photographs of the backs of each animal were taken once a week. Mice were killed under ether euthanasia at the end of week 25 and complete autopsy was performed. All skin tumors were subjected to histological examination after routine processing and hematoxylin and eosin staining. The experimental protocol was according to the guidelines for Animal Experiments in the National Cancer Center.
Immunohistochemical staining
Immunohistochemical analyses of skin tumor samples from female EP 3 À/À and wild-type mice were performed with the avidin-biotin complex immunoperoxidase technique, as previously reported (19) . As primary antibodies, monoclonal mouse anti-b-catenin and mouse anti-E-cadherin antibodies (Transduction Laboratories, Lexington, KY) were used at 100Â dilution (20) . As the secondary antibody, biotinylated anti-mouse IgG (HþL) raised in a horse, affinity purified, and absorbed with rat serum (Vector Laboratories, Burlingame, CA) was used at 200Â dilution. Staining was performed using avidin-biotin reagents (Vectastain ABC reagents; Vector Laboratories), 3, 3 0 -diaminobenzidine and hydrogen peroxide, and the sections were counterstained with hematoxylin to facilitate orientation. As a negative control, duplicate sections were immunostained without exposure to the primary antibody (20) .
Analysis of EP receptor expression in skin tumors by RT-PCR Total RNA was extracted from papillomas (5 mm or more in diameter), keratoacanthoma, SCCs and normal skin tissues by direct homogenization in ISOGEN (Nippon Gene, Tokyo, Japan), and spectrophotometry was used for quantification. Three microgram aliquots of total RNA were subjected to the RT reaction with random 9mer primers using an Omniscript Reverse Transcriptase kit (Qiagen, Hilden, Germany). After reverse transcription, PCR was carried out with HotStartaq (Qiagen), according to the manufacturer's instructions. To test cDNA integrity, the cyclopilin (PPIA) gene was amplified for each sample (21) . Primers were designed, based on published sequences from Genbank, using the computer program OLIGO 4.0-s (National Biosciences, MD). Primers were designed to cross an exon-exon boundary or insert an intron to ensure that genomic DNA was not being amplified. BLAST searches confirmed that the primers were specific for the target gene. Primers for the cyclopilin and EP receptor genes are listed in Table I . PCR amplification was performed in a thermal cycler (Gene Amp PCR System 9600, Perkin-Elmer Applied Biosystems, Foster City, CA), with 18-40 cycles of 94 C for 20 s, 60 C for 30 s, and 72 C for 1 min, using the specific primer sets. The PCR products were then analyzed by electrophoresis on 2% agarose gels.
Quantitative real-time RT-PCR analysis
Quantitative real-time RT-PCR analysis was performed using the Smart Cycler system with an Ex Taq R-PCR kit and SYBR Green (Takara Shuzo, Shiga, Japan) according to the manufacturer's instructions. Primers for the cyclopilin and EP 3 genes, and the cycle conditions for PCR are listed in Table I . To assess the specificity of each primer set, amplicons generated in PCR reactions were analyzed for their melting point curves and additionally run on 2% agarose gels to confirm the correct sizes of the PCR products. Each PCR product was subcloned into the TA cloning plasmid vector, pGEN-T easy vector (Promega, Madison, WI), and used as a positive control for real-time PCR analyses. The numbers of molecules of specific gene products in each sample were determined using a standard curve generated by amplification of 10 2 -10 8 copies of the control plasmid.
Statistical analysis
The significance of differences in the incidences of tumors was analyzed with the x 2 -test and other differences using the Student's t-test. Statistical significance was concluded at P 5 0.05.
Results
Macroscopic findings for skin carcinogenesis
The mean food intake and body weights of EP 3 receptorknockout mice were comparable with those of wild-type Figure 1 . Skin tumors began to appear at 7 weeks after DMBA treatment in wild-type mice, and at 10 weeks in EP 3 receptor-knockout mice ( Figure 1A) . Multiplicities of skin tumors at week 11 were significantly different in EP 3 receptor-knockout mice and wild-type mice (0.05 AE 0.05 versus 0.46 AE 0.18, P 5 0.05) ( Figure 1A and B) , but no significant differences in incidences were observed (1/19 versus 8/24, P 5 0.056). There were no significant differences in either incidences or multiplicities of macroscopic lesions at 25 weeks after TPA treatment ( Figure 1A and B) .
Histological findings for skin carcinogenesis Data for the histopathological diagnoses of skin tumors are summarized in Table II . Final incidences of skin tumors were 100% (19/19) and 95.8% (23/24), and multiplicities were 3.58 AE 0.51 and 3.17 AE 0.63 in EP 3 receptor-knockout mice and wild-type mice, respectively. The incidences and multiplicities of papillomas also did not differ between the groups. However, SCCs occurred in three wild-type mice, one with two lesions, but were not observed in EP 3 receptor-knockout mice. Instead of SCCs, keratoacanthomas were apparent in EP 3 receptor-knockout mice, but were not apparent in their wild-type counterparts (6/19 versus 0/24, P 5 0.01). Microscopical features of skin tumors observed in hematoxylin and eosin stained sections are illustrated in Figure 2 . One of the SCCs was moderately-differentiated and this lesion appeared as a solid mass forming shallow encrusted ulcers, with squamous epithelial cells proliferating downward and invading the adjacent subcutis and muscle (Figure 2A ). This SCC was composed of irregular masses of squamous epithelial cells and some spindle cells ( Figure 2B ). The other three SCCs were well-differentiated and featured irregular structures of squamous cells with well defined basal cell layers ( Figure 2C) , and a number of epithelial pearls in the basal cell layers ( Figure 2D ). All keratoacanthomas exhibited a characteristic bowl shape filled with mature keratin (Figure 2E ), and the walls had a buttress-like appearance. They were composed of thick, folded layers of welldifferentiated stratified squamous epithelium enclosed by a prominent basal layer, and the structure of stratified squamous epithelium was similar to normal epidermis ( Figure 2F ).
The four SCCs and six keratoacanthomas developed at 10, 11, 17, 20 and 12, 12, 14, 17, 17, 22 weeks after the beginning of TPA treatment, respectively. SCCs were originally observed as wart-like tumors in the shape of a dome without a stem, and then grew inside mouse skin. On the other hand, keratoacanthomas arose from papilloma-like tumors in the shape of a pole or a mushroom, and then grew on the surface of mouse skin into node-like or crater-like tumors.
The size distribution of papillomas (excluding SCCs and keratoacanthomas) is provided in Figure 3 . The number of papillomas 3 to 55 mm in diameter was significantly increased in EP 3 receptor-knockout compared with wild-type mice (0.68 AE 0.19 versus 0.22 AE 0.09, P 5 0.05).
Localization of E-cadherin and b-catenin in skin tumors
Immunohistochemical analysis of paraffin-embedded specimens of skin SCCs in wild-type mice ( Figure 4A-C) and keratoacanthomas in EP 3 receptor-knockout mice ( Figure 4D-F) was performed to examine the localization of cell-cell adhesion molecules E-cadherin and b-catenin, using specific antibodies. Sections without primary antibody treatment were also stained as negative controls (Figure 4A and D) . Reduced expression of E-cadherin in cellular membranes and abnormal localization of b-catenin in the cytoplasm were found in basal cells of SCCs ( Figure 4B and C) . In contrast, normal localization of E-cadherin and b-catenin were observed in basal cells of keratoacanthomas ( Figure 4E and F).
Expression of PGE 2 receptors in skin tumors
Expression of PGE 2 receptors in four samples each of DMBA/ TPA-treated mouse skin lesions and adjacent normal skin tissues were examined by RT-PCR. Expression of EP 1 , EP 2 and EP 4 receptor mRNAs in SCCs and keratoacanthomas was very similar to that in adjacent normal skin samples. EP 3 expression in keratoacanthomas and adjacent normal skin samples from EP 3 receptor-knockout mice could not be detected, in clear contrast to the positive results obtained for all SCC and adjacent normal skin samples in wild-type mice. However, expression of EP 3 receptor mRNA in skin SCCs of wild-type mice was markedly lower than that in normal skin tissue ( Figure 5A ). Quantitative real-time RT-PCR analysis Ã Significantly different from the corresponding wild-type value at P 5 0.05. suggested the EP 3 receptor to be downregulated in papillomas and SCCs to 5.7 and 17.1%, respectively, of the average value of normal skin tissues ( Figure 5B ).
Discussion
In the present study, examination of the significance of PGE 2 receptor EP 3 for two-stage DMBA/TPA skin carcinogenesis in EP 3 receptor-knockout mice showed no overall difference in incidences and multiplicities of papillomas at week 25, but a shift from SCC to keratoacanthoma development was evident, indicating that the EP 3 receptor may promote malignant change in skin carcinogenesis.
The EP 3 receptor is widely distributed throughout the body, and its mRNA has been identified in almost all tissues in mice and rats, as well as humans (11, 22, 23) . In situ hybridization analysis has revealed high level expression of EP 3 and EP 4 receptor mRNA in the dermal papilla cells of hair follicles (24) . We confirmed the prostaglandin E 2 receptors EP 1-4 to be expressed in wild-type mouse normal skin tissues by RT-PCR ( Figure 5A ), consistent with a previous report (25) .
TPA treatment is known to increase epidermal PGE 2 production in mice skin (10) , and PGE 2 promotes mast cell activation and IL-6 production through the EP 3 receptor (26-28). Furthermore, acute cutaneous inflammation induced by arachidonic acid is markedly attenuated in EP 3 receptorknockout mice (29) . Thus, PGE 2 /EP 3 signaling is considered to be a major pathway of acute inflammation in mouse skin. In the present study, macroscopic observation demonstrated that formation of tumors was delayed for 3 weeks in EP 3 receptorknockout mice, and multiplicity was significantly lower at week 11 than in wild-type mice. DMBA/TPA two-stage skin tumorigenesis using IL-6-knockout C57BL/6 mice also features a delay in tumor formation compared with wild-type mice (30) so that the delay of 3 weeks in formation of tumors in EP 3 receptor-knockout mice may have been caused by attenuation of acute inflammation due to deficiency of the EP 3 receptor. Therefore, it is important to determine whether the temporal delay in tumor formation in EP 3 receptor-knockout mice consequently influenced formation of keratoacanthomas. Examination of the time points of occurrence of the individual keratoacanthomas and SCCs, however, suggested no clear difference in the developing period between two types of tumor. Therefore, it is considered that the lack of SCCs in EP 3 -knockout mice was not simply due to a delay, but rather to a block in malignant development because of the EP 3 deficiency. Indeed, characteristic differences in generation of keratoacanthomas and SCCs were observed as macroscopic findings, described in the Results. These might reflect variation, especially regarding cell invasiveness, in the early promotion stage occurring in wild-type but not EP 3 receptorknockout mice. Clearly, a number of molecules downstream of the EP 3 receptor could play important roles in early stages of skin carcinogenesis; however, which are actually critical for SCC formation have yet to be clarified.
The present histological assessment suggested that tumor development in wild-type and EP 3 receptor-knockout mice distinctly differs (Figure 2) . The structural differences apparent between SCCs and keratoacanthomas would be expected to correlate with several factors including cell-cell adhesion, cell invasiveness and cell polarity, and this was confirmed by our immunohistochemical findings for adhesion molecules, E-cadherin and b-catenin. Chu et al. (31, 32) earlier reported E-cadherin and catenin (a-, b-and g-) to be normally localized in cell membranes of keratoacanthomas, whereas abnormal cytoplasmic localization or loss of expression are characteristic of SCCs and our results are in agreement.
There was no significant difference in incidences and multiplicities of tumor formation at the end point of the experiment as shown in Figure 1 and Table II . Although formation of tumors was delayed for 3 weeks in EP 3 receptor-knockout mice (Figure 1 ), papillomas of 3 to 55 mm in diameter were increased (Figure 3) , suggesting elevated proliferation of tumor cells. Indeed, our previous study has shown that downregulation of EP 3 receptor expression in colon cancer might be associated with increased multiplicity of lesions 2-5 mm in diameter. Furthermore, the EP 3 receptor-selective agonist, ONO-AE-248 decreases cell proliferation in the HCA-7 human colon adenocarcinoma cell line (15) . Konger et al. (33) reported that growth stimulation of human kerationocyte cells occurs via an EP 2 and/or EP 4 receptor-adenylate cyclase coupled response, while cell growth was inhibited by EP 3 receptor agonist sulprostone. Our studies, together with recent reports, suggest that the EP 3 receptor plays a role in suppression of skin epithelial cell proliferation and inhibits tumor growth.
The mouse EP 3 receptor has three isoforms, EP 3a , EP 3b and EP 3g generated by alternative splicing from the single EP 3 receptor gene. The major signaling pathway for the EP 3a and EP 3b receptors is inhibition of adenylate cyclase via G i (34, 35) . In contrast, the EP 2 and EP 4 receptors are coupled to G s and stimulate cAMP production by adenylate cyclase (11). Konger et al. (36) reported that inhibition of EP 2 receptor expression by its anti-sense construct in a HaCat immortalized human keratinocyte cell line, which expresses the EP 2 receptor predominantly and trace amounts of EP 3 and EP 4 receptors, is associated with decreased expression of paxillin, a critical component for focal adhesion assembly. Inhibition of EP 2 receptor expression decreased EP 2 agonist-induced cAMP production in HaCat cells, and endowed extensive deep invasion capacity in a 3D organ culture model of normal skin. Our findings provide indirect evidence that attenuation of cAMP production by PGE 2 via EP 3 receptor in keratinocyte cells might enhance neoplastic progression. It has been reported that the EP 3 selective agonist ONO-AE-248 blocks the rise in intracellular cAMP induced by forskolin, an activator of adenylate cyclase, in CHO cells transfected with EP 3a receptor (37) . Additional studies are now needed to investigate interactions between the EP 3 and other EP receptors in skin carcinogenesis.
In conclusion, our present data suggest that the PGE 2 receptor EP 3 may play a role in neoplastic progression in skin carcinogenesis.
